Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

heterodimeric interleukin-15

A fusion protein complex composed of heterodimeric IL-15 (hetIL-15), which consists of a synthetic form of the endogenous cytokine interleukin-15 chain (IL-15) complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain (IL-15Ra) (IL15:sIL-15Ra), with potential immunomodulatory, anti-infective and antineoplastic activities. Upon administration, hetIL-15 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbeta-gamma) receptor on natural killer (NK) and T-lymphocytes, which activates and increases the levels of NK cells and CD8+ and CD4+ T cells. The T cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. Altogether, this enhances tumor cell killing and decreases tumor cell proliferation. By coupling IL-15 to IL15Ra, this agent has an improved pharmacokinetic profile, shows an increased ability to bind IL-2Rbeta-gamma, and shows increased immunostimulatory activity as compared to IL-15 alone.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IL-15/sIL-15Ra
Abbreviation:heterodimeric IL-15
hetIL-15
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search